Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SCYXthis companySCYNEXIS, Inc.	$3.49	-3.67×	0.64×	1.53×	-1.54×	-706.6%	100.0%	-78.0%	-41.8%	-17.4%	-29.9%	-16.7%	0.04×	2.35×	-92.91×	7.04×	0.0%	2	-5.05	2	C+
CVKDCadrenal Therapeutics, Inc. Common Stock	$0.99	-1.02×	4.94×	0×	-0.72×	66.0%	0.0%	0.0%	0.0%	-483.3%	-491.5%	-93.2%	0×	0.3×	0×	2.72×	0.0%	2	-15.68	2	C+
NRXSNeurAxis, Inc.	$6.27	-4.78×	12.13×	11.55×	-4.79×	-170.9%	84.2%	-219.4%	-218.5%	-229.5%	-204.7%	-15.7%	0.12×	0.59×	-105.85×	2.05×	0.0%	3	5	1	C-
NXLNexalin Technology, Inc.	$1.46	-1.12×	2.44×	30.32×	-1.04×	-664.7%	79.7%	-2781.7%	-2725.8%	-219.4%	-223.9%	-54.2%	0×	0.08×	0×	4.85×	0.0%	3	-54.5	1	D+
TLPHTalphera, Inc.	$1.14	-3.35×	2.84×	1,726.72×	-3.41×	-102.6%	100.0%	-48157.1%	-51035.7%	-83.9%	-52.0%	-23.5%	0.38×	-0.04×	0×	5.49×	0.0%	3	-23.57	1	D+
XCURExicure, Inc.	$0.91	-6.86×	8.69×	0×	-5.97×	-65.3%	0.0%	0.0%	0.0%	-126.0%	-86.8%	-25.1%	0.04×	0.7×	-10,117×	1.19×	0.0%	1	-27.84	1	C-
Peer median	—	-3.35×	4.94×	11.55×	-3.41×	-102.6%	79.7%	-219.4%	-218.5%	-219.4%	-204.7%	-25.1%	0.04×	0.3×	0×	2.72×	0.0%	3	-23.57	1	—